Health Care • Precision Instruments
$75.46 ▲ +3.06
(+4.23%)
MKT CAP: $15.24B • VOL: 755.4K
52W L $63 52W H $108
ULS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.05B | $2.87B | $2.68B |
| YoY Revenue Growth % | +6.4% | +7.2% | — |
| Gross Profit | $1.51B | $1.39B | $1.18B |
| Gross Margin % | 49.5% | 48.5% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $522.0M | $462.0M | $368.0M |
| Operating Margin % | 17.1% | 16.1% | 13.7% |
| Net Income (GAAP) | $325.0M | $326.0M | $260.0M |
| EBITDA (Normalized) | $679.6M | $651.6M | $464.4M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $600.0M | $524.0M | $467.0M |
| Capital Expenditures (CapEx) | $197.0M | $237.0M | $120.5M |
| Free Cash Flow (FCF) | $403.0M | $287.0M | $346.5M |
| FCF Margin % | 13.2% | 10.0% | 12.9% |
| Return on Invested Capital (ROIC %) | 28.3% | 28.1% | 5.7% |
| Cash & Short-Term Equivalents | $295.0M | $298.0M | $921.7M |
| Total Debt (Short + Long Term) | $491.0M | $692.0M | $1.96B |
| Total Stockholders' Equity | $1.26B | $904.0M | $4.02B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ULS.